This article is more than 5 years old. Information may no longer be current.

CD22 Redirected Autologous T Cells for ALL

Issue: November/December 2019

Add topic to email alerts

Please provide your email address to receive an email when new articles are posted on Cell Therapy.

Subscribe

Added to email alerts

You've successfully added Cell Therapy to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added Cell Therapy to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Phase 1, single center, single arm, open-label pilot study to determine the feasibility and safety of a single dose administered as spilt fractions of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-zeta and 4-1BB (TCR-zeta/4-1BB) co-stimulatory domains (referred to as “CART22” cells) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia.